ImmuneOncia Therapeutics, Inc.

Sentiment around initial public offerings (IPOs) appears to be slowly recovering in South Korea as the market stabilizes somewhat amid ongoing political uncertainties at home and abroad. A couple of b

A series of initial public offering plans unveiled by South Korean biopharma firms, notably Orum Therapeutics Inc., is raising hopes of a recovery in the general funding situation in the sector. After

For Yuhan Corporation , the past several years have marked a new beginning in terms of the development and globalization of novel drugs, and the pursuit of an open innovation approach to R&D has been

Although the PD-1/PD-L1 market is rapidly becoming saturated, with several drugs already approved and many more candidates undergoing clinical trials, ImmuneOncia Therapeutics, Inc. is challenging t